High-Dose and High-Frequency Lanreotide Autogel in Acromegaly: A Randomized, Multicenter Study

New medical therapies of acromegaly

(2016) F. Maffezzoni et al.   GROWTH HORMONE & IGF RESEARCH

Optimizing Blood Sampling Protocols in Patients With Acromegaly for the Estimation of Growth Hormone Secretion

(2016) Ferdinand Roelfsema et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Treatment of acromegaly in the era of personalized and predictive medicine

(2015) Manuel Puig Domingo   CLINICAL ENDOCRINOLOGY

SAGIT®: clinician-reported outcome instrument for managing acromegaly in clinical practice—development and results from a pilot study

(2015) Andrea Giustina et al.   Pituitary

Interpreting biochemical control response rates with first-generation somatostatin analogues in acromegaly

(2015) Annamaria Colao et al.   Pituitary

Investigational drugs targeting somatostatin receptors for treatment of acromegaly and neuroendocrine tumors

(2014) Andrea Giustina et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Acromegaly Clinical Trial Methodology Impact on Reported Biochemical Efficacy Rates of Somatostatin Receptor Ligand Treatments: A Meta-Analysis

(2014) John D. Carmichael et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Successful Mortality Reduction and Control of Comorbidities in Patients With Acromegaly Followed at a Highly Specialized Multidisciplinary Clinic

(2014) Moises Mercado et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

The management of the patient with acromegaly and headache: A still open clinical challenge

(2014) A. Giustina et al.   JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION

Expert consensus document: A consensus on the medical treatment of acromegaly

(2014) Andrea Giustina et al.   Nature Reviews Endocrinology

Octreotide LAR treatment of acromegaly in “real life”: long-term outcome at a tertiary care center

(2014) Ana Laura Espinosa-de-los-Monteros et al.   Pituitary

Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial

(2014) Mônica R Gadelha et al.   Lancet Diabetes & Endocrinology

Efficacy, safety, and pharmacokinetics of sustained-release lanreotide (lanreotide Autogel) in Japanese patients with acromegaly or pituitary gigantism

(2013) Akira Shimatsu et al.   ENDOCRINE JOURNAL

Effects of Lanreotide Autogel on Growth Hormone, Insulinlike Growth Factor 1, and Tumor Size in Acromegaly: A 1-Year Prospective Multicenter Study

(2013) Roberto Attanasio et al.   Endocrine Practice

Vertebral Fractures in Patients With Acromegaly: A 3-Year Prospective Study

(2013) G. Mazziotti et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Tumor Shrinkage With Lanreotide Autogel 120 mg as Primary Therapy in Acromegaly: Results of a Prospective Multicenter Clinical Trial

(2013) Philippe J. Caron et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

A consensus on the diagnosis and treatment of acromegaly complications

(2012) S. Melmed et al.   Pituitary

Meta-Analysis on the Effects of Octreotide on Tumor Mass in Acromegaly

(2012) Andrea Giustina et al.   PLoS One

Effects of high-dose octreotide LAR on glucose metabolism in patients with acromegaly inadequately controlled by conventional somatostatin analog therapy

(2011) Gherardo Mazziotti et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

Clinical, quality of life, and economic value of acromegaly disease control

(2011) A. Ben-Shlomo et al.   Pituitary

A Consensus on Criteria for Cure of Acromegaly

(2010) A. Giustina et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Current management practices for acromegaly: an international survey

(2010) A. Giustina et al.   Pituitary

Clinical efficacy and safety results for dose escalation of somatostatin receptor ligands in patients with acromegaly: a literature review

(2010) Maria Fleseriu   Pituitary

Pituitary-independent effect of octreotide on IGF1 generation

(2009) Ana Pokrajac et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

High-dose intramuscular octreotide in patients with acromegaly inadequately controlled on conventional somatostatin analogue therapy: a randomised controlled trial

(2009) Andrea Giustina et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

Effects of Somatostatin Analogs on Glucose Homeostasis: A Metaanalysis of Acromegaly Studies

(2009) Gherardo Mazziotti et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Clinical Value of Monitoring Plasma Octreotide Levels During Chronic Octreotide Long-Acting Repeatable Therapy in Carcinoid Patients

(2009) Eugene A. Woltering et al.   PANCREAS

Effects of lanreotide SR and Autogel on tumor mass in patients with acromegaly: a systematic review

(2009) Gherardo Mazziotti et al.   Pituitary

A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly

(2008) I M Holdaway et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

Sleep apnoea syndrome is highly prevalent in acromegaly and only partially reversible after biochemical control of the disease

(2008) Maria Vittoria Davi' et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

A Critical Analysis of Clinically Available Somatostatin Analog Formulations for Therapy of Acromegaly

(2008) Robert D. Murray et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Divergence between Growth Hormone and Insulin-Like Growth Factor-I Concentrations in the Follow-Up of Acromegaly

(2008) Orsalia Alexopoulou et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Prognostic Significance of the Ki-67 Labeling Index in Growth Hormone-Secreting Pituitary Adenomas

(2008) A. Fusco et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM